Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/48526
Título: Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
Autores/as: Aguiar Bujanda, David
Bohn Sarmiento, Uriel
Cabrera Suárez, Miguel Ángel
Pavcovich Ruiz, Marta
Limeres González, Miguel Ángel 
Aguiar Morales, José
Clasificación UNESCO: 32 Ciencias médicas
320101 Oncología
Palabras clave: Cyclophosphamide
Carcinoma
Breast neoplasms
Chemotherapy
Fecha de publicación: 2006
Publicación seriada: Journal of Cancer Research and Clinical Oncology 
Resumen: Purpose: To assess the efficacy and the toxicity of a new combination of epirubicin, cyclophosphamide and paclitaxel as neoadjuvant chemotherapy for breast cancer. Methods: Patients with stage II and III breast cancer received 3-4 cycles of epirubicin 75 mg/m(2) plus cyclophosphamide 600 mg/m(2) on day 1, and paclitaxel at a dose of 100 mg on days 1, 8, 15 and 22 on a 28-day cycle. Results: Forty-nine patients were enrolled in the study. Stage II was present in 16 patients (32.7%) and stage III in 33 patients (67.3%). Relevant toxicities were nausea/vomiting grades III-IV in 6 patients (12.2%) and neutropenia grade III-IV in 33 patients (67.3%). The overall clinical response rate was 83.7%. Partial response was observed in 25 patients (51%), complete response in 16 patients (32.7%), stable disease in 7 patients (14.3%) and progression in 1 patient. Thirty-three non-inflammatory breast cancer patients underwent surgery, 29 with breast-conserving surgery (87.9%). Pathological complete response was found in 5 patients (15.1%). Conclusions: The combination of epirubicin, cyclophosphamide and weekly paclitaxel as given in this study is safe and shows good activity in the neoadjuvant setting of stage II and III breast cancer patients.
URI: http://hdl.handle.net/10553/48526
ISSN: 0171-5216
DOI: 10.1007/s00432-006-0079-7
Fuente: Journal of Cancer Research and Clinical Oncology[ISSN 0171-5216],v. 132, p. 332-338
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.